Introduction

Based on GLOBOCAN data in 2018, there are approximately 2.2% of all cancer diagnosed with neoplasms of the kidney. North America is one of the most incidences (Age-standardized rates (ASR) ASR = 10.9/100,000), including Western Europe (9.7) and New Zealand/Australia (9.6) [1]. Renal cell carcinoma (RCC) is the 7th most common form of neoplasm in developed countries. In the US, there is around 4.2% of all cancer diagnoses with 74,000 new cases of kidney diagnosed cancer in 2019. The incidence was firstly reported in 1975 as 7.1/100,000, while in 2016, this resulted in an incidence rate of 14.9/100,000, subsequently eliciting that kidney cancer is becoming one of the fastest-growing cancer diagnoses in the US. However, since culminating at 16.0/100,000 in 2008, kidney cancer incidence has plateaued [2].

In lower-middle countries, especially in Vietnam, although there are no completed statistics yet, RCC is still ranked 3rd in cancer disease of the urinary system. Nowadays, surgical treatment is still considered the backbone standard for kidney cancer treatment, while other treatments have not been effective [3, 4]. Laparoscopic nephrectomy was initially performed by Clayman et al in 1990 [5], thereby opening a revolution in the minimally invasive treatment of renal tumors. Currently, laparoscopic radical nephrectomy (LRN) is considered the standard method for treating local renal tumors that is not feasible with pN [6]. The advantage of laparoscopic surgery (LS) compared to open surgery is extremely clear and has been demonstrated in numerous recent studies [6]. The main controversy among the authors is about the safety and feasibility of LS for advanced tumors [6]. In Vietnam, LS for RCC has been performed over the last decade, then there have been many reports on the effectiveness of this method, but there are no studies evaluating the long-term outcome of LS for RCC and its feasibility in advanced stages. This article aims to report the long-term outcomes of 191 patients with local and advanced RCC who underwent retroperitoneal LRN (RLRN) in Vietnam, a lower-middle country.
Methods

**Study population**

Our study was carried out on 191 RCC patients who underwent RLRN at Viet Duc University Hospital (Hanoi) - one of the largest surgical centers in Vietnam, from February 2013 to March 2021.

**Ethics approval and consent to participate**

Written informed consent was obtained from all patients and their family members before participation. The study was approved by our research committee, Viet Duc University Hospital, Hanoi, Vietnam, and this was approved by Hanoi Medical University Institutional Ethical Review Board (No NCS07/BB-HDDD) date February 14, 2019.

**Human and animal rights**

No animals were used for studies that are the basis of this research. This research was conducted on humans in accordance with the Helsinki Declaration of 1975, as revised in 2013 (http://ethics.iit.edu/ecodes/node/3931).

Prospective and retrospective descriptive studies based on prebuilt case samples. Retrospective patient group: Collecting necessary data through medical records at the record-keeping room of Viet Duc University Hospital from February 2013 to January 2018. Prospective patient group: Includes patients diagnosed and treated between January 2018 and March 2021.

**Case-ascertainment**

Define: Indications of Surgery. Long-term outcome: >= 5 years. Criteria for patient selection: Patients with complete medical records, ultrasound, X-ray, multislice computer tomography (MSCT), were diagnosed with renal cell cancer; preoperative diagnosis at stage T1-3aN0-1M0 (based on computed tomography [CT]); opposite kidney with normal function: normal kidney function test, normal kidney morphology, no pathology in the contralateral kidney on ultrasound, MSCT; the pathology results showed that it was renal cell cancer; do not have other types of cancer.

**Follow-up**

The recorded data include preoperative characteristics of the patient and disease: history, clinical, liver, and kidney function tests, chest X-ray, ultrasound, CT; intraoperative and postoperative development: operative time, bleeding, vascular injury, organ damage, conversion to open surgery, lymphatic leakage, incision infection, re-operation; data on postoperative developments: length of hospital stay, time of defecation, duration of pain medication.

Patients were scheduled for reexamination for the first time, 1 month after surgery; then every 3 months in the first year, and every 6 months in the following years. Patients reexamined had chest X-ray, abdominal ultrasound, and blood test to evaluate kidney function. In the first year, take a CT scan every 6 months, in the following years take a CT scan once a year or when an ultrasound shows signs of recurrence.

At the end of the study in December 2021, determine the time and cause of death, the time and location of recurrence or distant metastasis.

Any recurrent mass in the ipsilateral fossa is considered local recurrence and metastasis anywhere outside this region is considered distant metastasis. Port site metastases were defined as tumor recurrence at the site of laparoscopic ports or specimen collection incision.

**Availability of data and materials**

The data supporting the findings of the article is available within the article.

**Supplementary material**

Supplementary material is available on the publisher’s website along with the published article.

**Statistical analysis**

All data are extracted from medical records and data analysis was performed by using IBM SPSS Statistics program, version 16, Statacorp LLC, TX, USA. Descriptive statistical analysis was used to describe patient characteristics (frequency and percentage for qualitative variables; mean and standard deviation for quantitative variables). Data of the groups were compared statistically using the Chi-square test and Fisher’s exact test for categorical variables, and one-way analysis of variance test for continuous variables. The primary endpoint of the study was cancer-specific survival (CSS), which was defined as the time from the date of surgery to cancer-specific death or last available follow-up. Patients were censored in case of non-RCC-related death or at the time of the last follow-up. Survival times were estimated with the Kaplan–Meier method and compared using the log-rank test. Kaplan–Meir survival analysis was used to estimate 5-year overall survival (OS), 5-year CSS, and 5-year recurrence-free survival (RFS). The log-rank test was used to compare survival rates among groups. Cox proportional hazard regression model was used to identify prognostic factors for patient mortality. All p values were two-sided and p < 0.05 was considered statistically significant.
Results

The clinical, intraoperative, and postoperative characteristics are shown in Table 1.

The average age and men/women ratio was 52.6 ± 13.2 and 1.48, respectively, while the average operative time was 86.8 ± 21.2 min. Herein, we observed that the operative time was significantly longer in the 3rd stage compared with stages 1 and 2 (p = 0.0001). Intraoperative bleeding is the main dangerous complication in 14 patients (7.3%) including vascular injury (6), ipsilateral adrenal gland injury, accompanying adrenalectomy (2), from dissection area and lymph node dissection (LND) (6), one patient had to be converted to open surgery due to massive bleeding. The average blood loss in these 14 patients was 137.5 ± 56.9 ml. Two patients had to reoperate on the 1st day due to postoperative bleeding: slip off hem-o-lok from the renal artery (1) and the lumbar artery (1). There was no difference in the rate of intraoperative and postoperative complications at 3 stages with p = 0.24 and p = 0.67. The length of hospitalization and duration of pain medication of the 3 groups were not statistically significant with p = 0.2164 and 0.6389.

Results by lymph node dissection (LND) group are shown in Table 2.

There were observed in 10 patients (5.2%) with no LND, 163 patients (85.3%) with limited LND, 13 patients (6.8%) with regional LND, and 5 patients (2.6%) with extended LND (eLND). Among these 5 patients with eLND, there was 1 patient who had pathologically lymph node (LN) metastasis. The average number of removed LNs was 3.9 ± 2.3 nodes with a minimum of 1 node and a maximum of 15 nodes. The average number of the eLND group was 7.6 nodes. eLND elicited only prolongation of operative time (p = 0.000), however, did not increase intraoperative complications as similar as prolonged the duration of analgesia and hospital stay compared to the remaining groups (p = 0.82, 0.85, 0.91).

Table 1: Histopathological results, follow-up record of the patients

| Characteristics          | Stage I (n = 134) | Stage II (n = 30) | Stage III (n = 27) | p-value | Total (%) (n = 191) |
|--------------------------|------------------|------------------|------------------|---------|---------------------|
| Age                      | 53.9 ± 13.1      | 47.1 ± 13.3      | 57.5 ± 11.6      | 0.01    | 52.6 ± 13.2         |
| Male/female              | 80/54            | 15/15            | 19/8             | 0.294   | 114/77              |
| Tumor size (mean ± SD)   | 46.6 ± 10.4      | 80.0 ± 13.1      | 58.6 ± 17.0      | 0.001   | 5.35 ± 1.7          |
| Incidental finding/symptomatic | 76/96            | 7/23             | 11/16            | 0.001   | 96/95               |
| RCC tumor subtypes (%)   | 134              | 30               | 27 (26+1)        |         | 191 (100)           |
| ccRCC                    | 90               | 17               | 17               |         | 124 (64.9)          |
| chRCC                    | 31               | 13               | 5                |         | 49 (25.7)           |
| pRCC                     | 8                | 0                | 3                |         | 11 (5.8)            |
| sRCC                     | 2                | 0                | 2                |         | 4 (2.1)             |
| Rare subtypes            | 3                | 0                | 0                |         | 3 (1.6)             |
| Fuhrman grade            | 100              | 17               | 21               |         | 138 (100)           |
| 1                        | 11               | 0                | 2                | 0.235   | 13 (9.4)            |
| 2                        | 65               | 10               | 10               |         | 86 (62.3)           |
| 3                        | 20               | 5                | 8                |         | 33 (23.9)           |
| Microvascular invasion (%) | 7 (5.2)         | 5 (16.7)         | 6/27 (22.2)      | 0.006   | 18 (9.4)            |
| Mean follow-up time (months) | 43.8 ± 25.5   | 40.6 ± 22.9      | 36.7 ± 22.4      | 0.48    | 42.3 ± 24.7         |
| PSM                      | 2                | 0                | 0                |         | 2 (1.0)             |
| Number of local recurrence | 1               | 0                | 2                |         | 3 (1.5)             |
| Number of distant metastasis (%) | 0       | 2                | 1                |         | 3 (1.5)             |
| Total mortality (%)      | 2                | 1                | 1                |         | 4 (2.1)             |
| Cancer-specific          | 2                | 1                | 1                |         | 4                  |
| Unrelated                | 0                | 0                | 0                |         | 0                  |
| OS/CSS (%)               | 98.9             | 100              | 91.3             | 0.0082  | 94.04               |
| RFS (%)                  | 98.3             | 100              | 88.7             | 0.0011  | 92.7                |

Table 2: Survival analysis after laparoscopic radical nephrectomy

| Research | Stage | T | N | M | Total | Tumor size (cm) | Follow-up (months) | PSM | Local recurrence | RFS 5y (%) | OS 5y (%) |
|----------|-------|---|---|---|-------|-----------------|-------------------|-----|-----------------|------------|-----------|
| Ono et al., 2001 [9] | T | N | M | Total | 5.0 | 29 | 0 | 1 | 95 | 95 |
| Portis et al., 2002 [10] | T | N | M | Total | 4.3 | 54 | 0 | 1 | 92 | 97 |
| Salika et al., 2003 [11] | T | N | M | Total | 3.7 | 40 | 0 | 0 | 91 | 94 |
| Permpongkossol et al., 2005 [12] | T | N | M | Total | 5.1 | 73 | 0 | 0 | 98 | 98* |
| Cheung et al., 2005 [13] | T | N | M | Total | 4.6 | 30 | 0 | 2 | 98 | - |
| Suer et al., 2013 [15] | T | N | M | Total | 7.3 | 36.67 | 0 | 0 | 88.6 | - |
| Hemal et al., 2007 [14] | T | N | M | Total | 4.21 | 56 | 0 | 0 | 84.3–97.2 | 86.3–97.2* |
| Suer et al., 2013 [15] | T | N | M | Total | 9.9 | 57.9 | 0 | 0 | 82 | 82* |

*CSS: Port site metastases, OS: Overall survival, RFS: Recurrence free survival, CSS: Cancer specific survival.
Pathological features and distant follow-up

Third stage had 27 patients, including pT3aN0M0 (26) and pT3aN1M0 (1). There was no difference in the male/female ratio between the 3 periods (p = 0.294). Stages 2 and 3 tumors were significantly larger than Stage 1 (p = 0.001), and had a higher proportion of patients with symptoms/accidental discovery (p = 0.001). Patients in Stage 3 had a higher mean age (p = 0.001). There was no difference in the distribution of histological type and Fuhrman grade in the 3 Stage groups, however, the highest rate of Sarcomatoid RCC (sRCC) was 7.4% in pT3a compared to 1.49% for pT1 and 0% for pT2. The median follow-up time was 42.3 ± 24.7 months (from 10 to 105 months). 5-years OS and 5-years RFS at Stage 3 were significantly lower than pT1-2 (p = 0.0011 and p = 0.0082, respectively) as shown in Table 1.

At the end of the study, 187 (97.9%) patients were still alive, 8 patients had a recurrence and/or distant metastasis, of which 4 (2.1%) patients died of RCC, and no patient died of other causes. Two patients proceeded with other cancers unrelated to RCC, including adenocarcinoma of the rectum (1) and lung adenocarcinoma, non-small-cell lung cancer (1). Two patients showed port site recurrence: one patient with sRCC pT1bN0M0, intact specimen, and one patient with Clear cell (ccRCC) pT1bN0M0 F4, microvascular invasion, specimen obtained by morcellation with the substandard bag. Local recurrence in 3 patients: ccRCC-pT1bN1M0-F2 (1); ccRCC-pT3aN0M0-F2 (1); ccRCC-pT1bN0M0-F3 (1). Distant metastasis in 3 patients: sRCC-pT3aN0M0 (1): brain and lung metastasis; ccRCC-pT2aN0M0-F3 (1): brain and lung metastasis; ccRCC-pT2aN0M0-F2 (1): liver metastasis.

Kaplan–Meier curves for patients in pT1, pT2, and pT3a of RFS and OS are presented in Figure 1a and b, respectively. The 5-year RFS, 5-year OS (CSS) were significantly lower in pT3a + N1 compared to pT1-2N0M0 (p = 0.0011 and 0.0082, respectively).

Discussion

Patient characteristics

RCC accounts for 90% of renal malignancies and ranks in 3rd among urological malignancies. The disease occurs in both sexes, the cause is not really clear, but some factors have been shown to increase the risk of RCC, such as smoking, being overweight or obese, or hereditary diseases such as Von Hippel-Lindau syndrome, Hereditary Papillary Renal Carcinoma, Birt- Hogg- Dubé syndrome [7]. In the present study, the mean age of the disease was 52.6 ± 13.3, the lowest age was 18 year old, and the highest age was 88-year-old, while the most common age was approximately 40-60 years old, the male/female ratio was 1.41. Research by A.K. Hemal (2007) also reported similar results, the mean age of the laparoscopic nephrectomy group was 52.5 ± 11.3 and the male/female ratio was 1.73 [8].
Long-term follow-up surgery

All 191 patients were reexamined, or information was obtained through phone and email interviews. The mean follow-up time was 42.3 ± 24.7 months, the shortest was 10 months, and the longest was 105 months. At the end of the study, 187/191 patients were alive, 8 patients had a recurrence or distant metastasis, 4 of which (2.1%) had died, including pT_3 (2), pT_4 (1), and pT_3a (1). The earliest death is 14 months; the latest is 102 months after nephrectomy.

RFS5-years in period 1–2–3 were 98.3%, 100%, 87.8% and OSS5-years in period 1–2–3 were 98.9%, 100%, 91.3%, respectively. Our results are similar when compared to other authors (Table 2).

**Table 3: Intra- and post-operative characteristics according to lymph node dissection**

| Characteristics                  | Total | LND limited and no region | Region | Extend | p   |
|----------------------------------|-------|---------------------------|--------|--------|-----|
| Bleeding complications           |       |                           |        |        |     |
| No                               | 177   | (92.7)                    | 102 (93.6) | 11 (84.6) | 4 (80) | 0.264 |
| Yes                              | 14    | (7.3)                     | 11 (6.4)  | 2 (15.4) | 1 (20) | 0.000 |
| Operating time (min)             | 86.9 ± 21.2 | 86.9 ± 21.5 | 84.6 ± 15.6 | 102 ± 20.5 | 0.000 |
| mean ± SD                        | 3.5 ± 0.8 | 3.5 ± 0.7 | 3.6 ± 0.6 | 3.4 ± 0.5 | 0.85 |
| Painkiller time (days)           | 5.04 ± 1.1 | 5.05 ± 1.2 | 4.8 ± 0.4 | 5.0 ± 0.0 | 0.91 |
| mean ± SD                        |       |                           |        |        |     |

**Indication of laparoscopic radical nephrectomy for advanced renal cell carcinoma**

Indications for LS at this stage are still controversial about its safety and effectiveness compared to traditional open surgery.

**Lymph node dissection**

Although the presence of LN metastases suggests a poor prognosis, the role of LND in treatment remains unclear. According to Giuliani, 6% of patients had regional LN metastases for local tumors, 46% for locally advanced tumors, and 62% for tumors with distant metastases [18]. However, many reports do not show the role of LND in improving survival [19], Minervini (2001) identified the 5-year survival between 2 groups of LND and no LND was 79% and 78% and found that there was no difference [20]. European Association of Urology (EAU) and American Urological Association (AUA) Guideline indicated that LND is not recommended for local tumors and there was no evidence of LN metastasis. However, LND may be valuable in high-risk groups, such as tumors over 10cm, T_3a; Furman 3–4, sRCC, tumor necrosis and when LN metastasis is suspected intraoperatively or on preoperative imaging [6], [21]. Phillip (1993) showed that regional LND reduced the local recurrence rate from 11% to 2.5%–8% [22]. The number of LN metastases (</= 4) was similar to the intracapsular and extracapsular extension of intra-nodal metastasis correlated with the patients’ clinical prognosis in several studies. Better survival outcomes were observed in patients with a low number of positive LNs (<4) and no extranodal extension [23], [24]. Whitson et al. (2011) retrospective surveillance with more than 9000 patients indicated that eLND had no effect on Disease-specific survival (DSS) in patients with negative lymph node findings on pathology. However, in patients with pathologically proven lymphogenic spread (pN+), an increase of 10 in the number of nodes dissected resulted in a 10% absolute increase in DSS [25]. In addition, in a larger cohort of 1983 patients, Capitanio et al. demonstrated that eLND results in a significant prolongation of CSS in patients with unfavorable prognostic features (sarcomatoid differentiation, large tumor size) [26]. Gershman B (2018) from a large single-center database showed that eLND is not associated with an increased risk of Clavien grade ≥3 complications. Furthermore, LND was not associated with the length of hospital stay or estimated blood loss [27]. Many authors agree that laparoscopic LND is safe and feasible and necessary in suspected cases, and the overall risk of complications was similar between the 2 groups (with lymphadenectomy and without lymphadenectomy) [28], [29].

In our study, LND was performed in 181 patients (95.3%), mainly limited LND 85.3% (163/191), region LND 13/191 (6.8%), and 5 patients (2.6%) suspected LN metastasis based on CT scan with eLND. Pathological results have 1 patient with positive LN (in the group of eLND). This patient had a local recurrence 13 months after LRN. We did not perform routine LND during nephrectomy. However, LNs along the renal vessels are often removed as part of a radical nephrectomy (limited LND). Our results (Table 3 and Figure 1c) elicited that laparoscopic eLND is potentially safe, but it only requires increasing the operating time but does not enhance the rate of intraoperative complications as similar as the postoperative outcome.

**Table 3: Intra- and post-operative characteristics according to lymph node dissection**

| Characteristics                  | Total | LND limited and no region | Region | Extend | p   |
|----------------------------------|-------|---------------------------|--------|--------|-----|
| Bleeding complications           |       |                           |        |        |     |
| No                               | 177   | (92.7)                    | 102 (93.6) | 11 (84.6) | 4 (80) | 0.264 |
| Yes                              | 14    | (7.3)                     | 11 (6.4)  | 2 (15.4) | 1 (20) | 0.000 |
| Operating time (min)             | 86.9 ± 21.2 | 86.9 ± 21.5 | 84.6 ± 15.6 | 102 ± 20.5 | 0.000 |
| mean ± SD                        | 3.5 ± 0.8 | 3.5 ± 0.7 | 3.6 ± 0.6 | 3.4 ± 0.5 | 0.85 |
| Painkiller time (days)           | 5.04 ± 1.1 | 5.05 ± 1.2 | 4.8 ± 0.4 | 5.0 ± 0.0 | 0.91 |
| mean ± SD                        |       |                           |        |        |     |

**Indication of laparoscopic radical nephrectomy in T_3a tumors**

T_3a (AJCC) locally advanced tumor: the tumor proceeds into the renal vein or its segmental branches, or invades the pelvicalyceal system or invades the perirenal and/or renal sinus fat, but not beyond gerota fascia. 4–10% of RCCs have venous thrombosis, of which 50–75% are found in the right renal tumor. Venous thrombosis is one of the poor prognostic factors [30]. However, in RCC without metastases, thrombectomy surgery significantly improves survival, 5-year survival rate according to several reports from 18% to 68% [31], [32]. Thrombectomy is a difficult technique and is often performed under traditional open surgery, however, LS is increasingly being used in some centers to allow removal of level 0, I or II thrombus. Preliminary results have demonstrated LS to be safe and feasible in selected patients [30]. The outcome of LRN at T_3a compared with
Table 4: Patient and disease characteristics, intra-operative and post-operative data

| Characteristics                          | Stage I (pT1aN0Mx) | Stage II (pT1bN0Mx) | Stage III (pT1-2aN1Mx) | p-value | Total (%) |
|-----------------------------------------|---------------------|----------------------|------------------------|---------|-----------|
| Number of patients                      | 134                 | 30                   | 27                     |         | 191       |
| Mean age (years)                        | 53.0 ± 13.1         | 57.0 ± 16.6          | 57.0 ± 16.6            | 0.01    | 52.6 ± 13.2 |
| BMI                                      | 22.4 ± 2.4          | 22.4 ± 2.2           | 22.4 ± 2.2             | 0.94    | 22.4 ± 2.2 |
| Men/women                               | 80/64               | 18/8                 | 18/8                   | 0.294   | 114/77    |
| Incidental findings/symptomatic         | 7/23                | 11/16                | 11/16                  | 0.001   | 96/95     |
| Mean tumor size (cm)                    | 46.6 ± 10.4         | 80.0 ± 13.1          | 58.6 ± 17.0            | 0.001   | 53.5 ± 1.7 |
| Mean operating time (min)               | 82.5 ± 20.3         | 89.0 ± 18.7          | 105.2 ± 18.5           | 0.0001  | 86.8 ± 21.2 |

| Intraoperative complications            |                     |                      |                        |         |           |
|-----------------------------------------|---------------------|----------------------|------------------------|---------|-----------|
| Vascular injury                         | 4                   | 1                    | 1                      |         | 6 (3.1)   |
| Bleeding                                | 8                   | 2                    | 4                      |         | 14 (7.3)  |
| Adrenal gland injury                    | 2                   | 2                    | 0                      |         | 2 (1.0)   |
| Conversions to open (%)                 | 0                   | 0                    | 1                      |         | 1 (0.5)   |
| Total (%)                               | 8                   | 2                    | 4                      | 0.24    | 14 (7.3)  |

| Post-operative complications            |                     |                      |                        |         |           |
|-----------------------------------------|---------------------|----------------------|------------------------|---------|-----------|
| Wound infection                         | 1                   | 1                    | 0                      |         | 2         |
| Re-operation due to bleeding            | 1                   | 0                    | 1                      |         | 2         |
| Lymphatic leak                          | 0                   | 0                    | 0                      |         | 0         |
| Total (%)                               | 2                   | 1                    | 1                      | 0.67    | 4 (2.1)   |

| Mean painkiller time (days)             | 3.5 ± 0.76          | 3.5 ± 0.68           | 3.7 ± 0.88             | 0.6389  | 3.52 ± 0.77 |
| Mean hospital stay (days)               | 5.03 ± 1.03         | 4.8 ± 1.3            | 5.3 ± 1.5              | 0.2164  | 5.6 ± 1.1  |

BMI: Body mass index.

Conclusion

Retroperitoneal LRN for RCC stage T1-2 gives results comparable to open surgery and presents outstanding advantages. For the advanced stage, LS has been shown to be safe and feasible for eLND as well as in the management of T3a tumors, positive long-term results of LS at this stage have also been reported. We believe that LRN should be the first choice for the management of stage T1-2-3aN1 renal tumors that are not feasible with partial nephrectomy.

Limitation of the study

In Vietnam, we have just implemented RLRN for patients with stage T3a and enlarged LND, so the number of patients in these 2 groups is small and the follow-up time is not enough. Therefore, we can only draw preliminary conclusions in their research. However, we will continue to perform RLRN with a larger number of patients and longer follow-up in the T3aN1M0 group and continuously do report the results in the near future.

Acknowledgements

We would like to thank to Dr. D.-H.B for his insightful commentary on the study design and paper preparation.

Author Contribution

Study concept and design: H.H.N, T.T.Do. Operated patients: H.H.N, T.T.D, L.H, M.D.N, S.N.D.
References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492
PMid:30207593

2. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Ferlay J, Fraumeni JF Jr, eds. SEER Cancer Statistics Review, 1975–2016. Bethesda, MD, USA: National Cancer Institute; 2017.

3. De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, et al. Critical revision of the manuscript: T.T.D, L.H. Drafting of manuscripts: H.H.N, L.H, T.C.V. Data acquisition: H.H.N, M.D.N. Data analysis: H.H.N, B - Clinical Sciences Surgery, Varkarakis I, et al.

4. Gunnarsson O, Pfanzelter NR, Cohen RB, Keefe SM. Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma. Cancer Manag Res. 2015;7:65-73. https://doi.org/10.2147/CMAR.S74202
PMid:25704999

5. Clayman RV, Kavoussi LR, Soper NJ, Dierks SM, Merety KS, et al. Laparoscopic nephrectomy. N Engl J Med. 1991;324(19):1370-1. https://doi.org/10.1056/NEJM199105093241917
PMid:1826761

6. Ljungberg B, Albiger L, Abu-Ghanem Y, Bansalak K, Dabestani S, Fernández-Pello S, et al. European Association of Urology guidelines on renal cell carcinoma: The 2019 update. Eur Urol. 2019;75(5):799-810. https://doi.org/10.1016/j.eururo.2019.02.011
PMid:30803729

7. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. https://doi.org/10.3322/caac.21590
PMid:31912902

8. Hemal AK, Kumar A, Gupta NP, Kumar R, Wadhwa P, Seth A, Gupta NP. Laparoscopic versus open radical nephrectomy for large renal tumors: A long-term prospective comparison. J Urol. 2007;177(3):862-6. https://doi.org/10.1016/j.juro.2006.10.053
PMid:17296361

9. Ono Y, Kinukawa T, Hattori R, Gotot M, Kamihira O, Ohshima S. The long-term outcome of laparoscopic radical nephrectomy for small renal cell carcinoma. J Urol. 2001;165(6) Part 1:1867-70. https://doi.org/10.1097/01.ju.000005392-200106000-00006
PMid:11371869

10. Portis AJ, Yan Y, Landman J, Chen C, Barrett PH, Fentie DD, et al. Long-term followup after laparoscopic radical nephrectomy. J Urol. 2002;167(3):1257-62. PMid:11832709

11. Saika T, Ono Y, Hattori R, Gotot M, Kamihira O, Yoshikawa Y, et al. Long-term outcome of laparoscopic radical nephrectomy for pathologic T1 renal cell carcinoma. Urology. 2003;62(6):1018-23. https://doi.org/10.1016/j.urology.2003.07.009
PMid:14665347

12. Permpongkosol S, Chan DY, Link RE, Sroka M, Allaf M, Varkarakis I, et al. Long-term survival analysis after laparoscopic radical nephrectomy. J Urol. 2005;174(4):1222-5. https://doi.org/10.1097/01.ju.0000173917.37265.41
PMid:16145374

13. Cheung M, Lee Y, Rindani R, Lau H. Oncological outcome of 100 laparoscopic radical nephrectomies for clinically localized renal cell carcinoma. ANZ J Surg. 2005;75(7):593-6. https://doi.org/10.1111/j.1445-2197.2005.03439.x
PMid:15972054

14. Hemal AK, Kumar A, Gupta NP, Kumar R. Oncologic outcome of 132 cases of laparoscopic radical nephrectomy with intact specimen removal for T1-2N0M0 renal cell carcinoma. World J Urol. 2007;25(6):619-26. https://doi.org/10.1007/s00345-007-0210-7
PMid:17786453

15. Süber E, Baltaci S, Burgu A, Aydogdu O, Gögücü S. Significance of tumor size in renal cell cancer with perinephric fat infiltration: Is TNM staging system adequate for predicting prognosis?. Urol J. 2013;10(1):774-9. PMid:23504681

16. Brookman-May SD, May M, Wolff I, Zuger E, Hutterer GC, Cindolo L, et al. CORONA Project; European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Group: Evaluation of the prognostic significance of perirenal fat invasion and tumor size in patients with pT1-pT3a localized renal cell carcinoma in a comp. Eur Urol. 2015;67(5):943-51. https://doi.org/10.1016/j.eururo.2014.11.055
PMid:25684695

17. Zhang YS, Yu HY, Dong F, Li HZ. Survival analysis of surgically treated renal cell carcinoma: An analysis of 10-year data from single center. Zhonghua Wai Ke Za Zhi. 2016;54(7):528-33. https://doi.org/10.3760/cma.j.issn.0529-5815.2016.07.011
PMid:27373480

18. Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: Long-term results and prognostic factors. J Urol. 1990;143(3):468-73. https://doi.org/10.1016/s0022-5347(17)39992-5
PMid:2304155

19. Gershman B, Thompson RH, Boorjian SA, Larcher A, Capitanio U, Montorsi F, et al. Radical nephrectomy with or without lymph node dissection for high risk nonmetastatic renal cell carcinoma: A multi-institutional analysis. J Urol. 2018;199(5):1143-8. https://doi.org/10.1016/j.juro.2017.11.114
PMid:29225056

20. Minervini A, Lilas L, Morelli G, Traversi C, Battaglia S, Cristofani R, et al. Regional lymph node dissection in the treatment of renal cell carcinoma: Is it useful in patients with no suspected adenopathy before or during surgery?. BJU Int. 2001;88(3):169-72. https://doi.org/10.1046/j.1464-410x.2001.02315.x
PMid:11488722

21. Campbell SC, Clark PE, Chang SS, Karam JA, Souter L, Uzzo RG, et al. Renal mass and localized renal cancer: AUA guideline. J Urol. 2017;198(3):520-9. https://doi.org/10.1016/j.juro.2017.04.100
PMid:28479239

22. Phillips E, Messing EM. Role of lymphadenectomy in the treatment of renal cell carcinoma. Urology. 1993;41(1):9-15. https://doi.org/10.1016/0090-4295(93)90234-2
PMid:8420090

23. Capitanio U, Becker F, Blute ML, Mulders P, Patard JJ, Russo P, et al. Lymph node dissection in renal cell carcinoma. Eur Urol. 2011;60(6):1212-20. https://doi.org/10.1016/j.eururo.2011.08.003
PMid:21940096

24. Kim S, Thompson RH, Weight C, Cheville J, Lohse C, Boorjian S, et al. “573 the relationship of lymph node dissection with recurrence and survival for patients treated with nephrectomy

2058 https://oamjms.eu/index.php/mjms/index
for high-risk renal cell carcinoma. J Urol. 2012;187(4S):e233-4. https://doi.org/10.1016/j.juro.2012.02.649

25. Whitson JM, Harris CR, Reese AC, Meng MV. Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases. J Urol. 2011;185(5):1615-20. https://doi.org/10.1016/j.juro.2010.12.053

26. Capitanio U, Suand N, Matloob R, Roscigno M, Abdollah F, Di Trapani E, et al. Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC). BJU Int. 2014;114(2):210-5. https://doi.org/10.1111/bju.12508
PMid:24854206

27. Gershman B, Moreira DM, Thompson RH, Boorjian SA, Lohse CM, Costello BA, et al. Perioperative morbidity of lymph node dissection for renal cell carcinoma: A propensity score-based analysis. Eur Urol. 2018;73(3):469-75. https://doi.org/10.1016/j.eururo.2017.10.020
PMid:29132713

28. Ono Y, Hattori R, Gotoh M, Yoshino Y, Yoshikawa Y, Kamihira O. Laparoscopic radical nephrectomy for renal cell carcinoma: The standard of care already?. Curr Opin Urol. 2005;15(2):75-8. https://doi.org/10.1097/01.mou.0000160619.28613.3c
PMid:15725928

29. Chapman TN, Sharma S, Zhang S, Wong MK, Kim HL. Laparoscopic lymph node dissection in clinically node-negative patients undergoing laparoscopic nephrectomy for renal carcinoma. Urology. 2008;71(2):287-91. https://doi.org/10.1016/j.urology.2007.08.057
PMid:18308105

30. Bansal RK, Tu HY, Drachenberg D, Shayaneg B, Matsumoto E, Whelan JP, et al. Laparoscopic management of advanced renal cell carcinoma with renal vein and inferior vena cava thrombus. Urology. 2014;83(4):812-6. https://doi.org/10.1016/j.urology.2013.09.060
PMid:24411219

31. Blute ML, Leibovich BC, Lohse CM, Cheville JC, Zincke H. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int. 2004;94(1):33-41. https://doi.org/10.1111/j.1464-410X.2004.04897.x
PMid:15217427

32. Schimmer C, Hillig F, Riedmiller H, Elert O. Surgical treatment of renal cell carcinoma with intravascular extension. Interact Cardiovasc Thorac Surg. 2004;3(20):395-7. https://doi.org/10.1016/j.ijcts.2004.02.014
PMid:17670271

33. Bolton EM, Hennessy D, Lonergan PE, Darcy FT, Manecksha RP, Lynch TH. Evaluating the perioperative safety of laparoscopic radical nephrectomy for large, non-metastatic renal tumours: A comparative analysis of T1-T2 with T3a tumours. Irish J Med Sci. 1971;187(2):313-8. https://doi.org/10.1007/s11845-017-1652-6
PMid:28702828

34. Slujewski M, Goląb A, Petrasz P, Sikorski A. Laparoscopic radical nephrectomy for T3b tumor. J Laparoendosc Adv Surg Tech. 2010;20(1):47-9. https://doi.org/10.1089/lap.2009.0258
PMid:20100060

35. Desai MM, Gill IS, Ramani AP, Matin SF, Kaouk JH, Camargo JM. Laparoscopic radical nephrectomy for cancer with level I renal vein involvement. J Urol. 2003;169(2):487-91. https://doi.org/10.1097/01.ju.0000041955.93458.1f
PMid:12544294

36. Barbas-Bernardos G, Herranz-Amo F, Caño-Velasco J, Gonzalo-Balbás Á, Subirá-Ríos D, Moralejo-Gáraste M, et al. Effect of surgical approach on radical nephrectomy outcomes: Comparative study between open and laparoscopic nephrectomy. Arch Esp Urol. 2020;73(3):172-82. https://doi.org/10.1080/0003980X.2019.1687327
PMid:32240107

37. Tian X, Hong P, Liu Z, Huang Y, Wang G, Hou X, et al. En bloc retroperitoneal laparoscopic radical nephrectomy with inferior vena cava thrombectomy for renal cell carcinoma with level 0 to II venous tumor thrombus: A single-center experience. Cancer. 2020;126:2073-8. https://doi.org/10.1002/cncr.32747
PMid:32293727

Supplementary Figure

**Supplemental Figure 1:** (a) T3a - renal vein thrombosis. (b) Preoperative T3aN1 → Postoperative T3aN0.